Original Article

You have full text access to this OnlineOpen article

Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells

  1. Shanmugam Muruganandan,
  2. Alexandra A Roman,
  3. Christopher J Sinal*

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.091106

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 2, pages 222–234, February 2010

Additional Information

How to Cite

Muruganandan, S., Roman, A. A. and Sinal, C. J. (2010), Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res, 25: 222–234. doi: 10.1359/jbmr.091106

Author Information

  1. Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada

*Department of Pharmacology, Dalhousie University, Tupper Medical Building, Room 5E, 5850 College Street, Halifax, Nova Scotia, Canada.

Publication History

  1. Issue published online: 19 FEB 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 20 NOV 2009
  4. Manuscript Revised: 19 AUG 2009
  5. Manuscript Received: 26 FEB 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (622K)

References

  • 1
    Phinney DG, Kopen G, Isaacson RL, Prockop DJ. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell Biochem. 1999; 72: 570–585.
  • 2
    Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci. 1992; 102: 341–351.
  • 3
    Post S, Abdallah BM, Bentzon JF, Kassem M. Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. Bone. 2008; 43: 32–39.
  • 4
    Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross-talk with the osteoblastogenic program. Cell Mol Life Sci. 2009; 66: 236–253.
  • 5
    Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab. 2008; 93: 2281–2286.
  • 6
    Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res. 2007; 22: 1720–1731.
  • 7
    Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue: a quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971; 80: 147–154.
  • 8
    Duque G, Troen BR. Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome. J Am Geriatr Soc. 2008; 56: 935–941.
  • 9
    Duque G. Will reducing adopogenesis in bone increase bone mass? PPARγ2 as a key target in the treatment of age-related bone loss. Drug News Perspect. 2003; 16: 341–346.
  • 10
    Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002; 143: 2376–2384.
  • 11
    Akune T, Ohba S, Kamekura S, et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113: 846–855.
  • 12
    Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89: 747–754.
  • 13
    Lian JB, Stein GS. Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Des. 2003; 9: 2677–2685.
  • 14
    Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, Lowik CW. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res. 2002; 17: 394–405.
  • 15
    Duque G, Macoritto M, Kremer R. 1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2). Exp Gerontol. 2004; 39: 333–338.
  • 16
    Okazaki R, Inoue D, Shibata M, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) α or β. Endocrinology. 2002; 143: 2349–2356.
  • 17
    Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology. 2001; 2: 165–171.
  • 18
    Gomez-Ambrosi J, Rodriguez A, Catalan V, Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg. 2008; 18: 1134–1143.
  • 19
    Burguera B, Hofbauer LC, Thomas T, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology. 2001; 142: 3546–3553.
  • 20
    Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005; 331: 520–526.
  • 21
    Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005; 309: 99–109.
  • 22
    Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999; 140: 1630–1638.
  • 23
    Yokota T, Meka CS, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002; 109: 1303–1310.
  • 24
    Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148: 4687–4694.
  • 25
    Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282: 28175–28188.
  • 26
    Zabel BA, Nakae S, Zuniga L, et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008; 205: 2207–2220.
  • 27
    Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol. 2003; 123: 702–711.
  • 28
    Janderova L, McNeil M, Murrell AN, Mynatt RL, Smith SR. Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obes Res. 2003; 11: 65–74.
  • 29
    Rougier F, Dupuis F, Denizot Y. Human bone marrow fibroblasts: an overview of their characterization, proliferation and inflammatory mediator production. Hematol Cell Ther. 1996; 38: 241–246.
  • 30
    Tang QQ, Lane MD. Activation and centromeric localization of CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte differentiation. Genes Dev. 1999; 13: 2231–2241.
  • 31
    Elabd C, Basillais A, Beaupied H, et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells. 2008; 26: 2399–2407.
  • 32
    Park SR, Oreffo RO, Triffitt JT. Interconversion potential of cloned human marrow adipocytes in vitro. Bone. 1999; 24: 549–554.
  • 33
    Gregory CA, Gunn WG, Peister A, Prockop DJ. An alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem. 2004; 329: 77–84.
  • 34
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101–1108.
  • 35
    Thompson DL, Lum KD, Nygaard SC, et al. The derivation and characterization of stromal cell lines from the bone marrow of p53–/– mice: new insights into osteoblast and adipocyte differentiation. J Bone Miner Res. 1998; 13: 195–204.
  • 36
    MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem. 1995; 64: 345–373.
  • 37
    Tang QQ, Otto TC, Lane MD. Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci USA. 2003; 100: 44–49.
  • 38
    Roh SG, Song SH, Choi KC, et al. Chemerin: a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007; 362: 1013–1018.
  • 39
    Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 2008; 582: 573–578.
  • 40
    Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005; 175: 487–493.
  • 41
    Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003; 198: 977–985.
  • 42
    Zabel BA, Ohyama T, Zuniga L, et al. Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-β and TLR ligands. Exp Hematol. 2006; 34: 1106–1114.
  • 43
    Cash JL, Hart R, Russ A, et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med. 2008; 205: 767–775.
  • 44
    Barak Y, Nelson MC, Ong ES, et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999; 4: 585–595.
  • 45
    Rosen ED, Sarraf P, Troy AE, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999; 4: 611–617.
  • 46
    Farmer SR. Regulation of PPARγ activity during adipogenesis. Int J Obes (Lond). 2005; 29: S13–S16.
  • 47
    Otto TC, Lane MD. Adipose development: from stem cell to adipocyte. Crit Rev Biochem Mol Biol. 2005; 40: 229–242.
  • 48
    Li X, Jin L, Cui Q, Wang GJ, Balian G. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int. 2005; 16: 101–108.
  • 49
    Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican American population. J Clin Endocrinol Metab. 2009; 94: 3085–3088.
  • 50
    Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population: a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152: 217–221.
View Full Article (HTML) Get PDF (622K)